Acta materia medica最新文献

New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives. 乳腺癌中的新一代雌激素受体靶向药物：现状与前景。

Acta materia medica Pub Date : 2024-02-21 Epub Date: 2024-03-15 DOI: 10.15212/amm-2024-0006

Jian Min, Xin Liu, Rouming Peng, Chun-Chi Chen, Wei Wang, Rey-Ting Guo

引用次数: 0

Application of PROTACs in Target Identification and Target Validation. PROTACs 在目标识别和目标验证中的应用。

Acta materia medica Pub Date : 2024-02-21 Epub Date: 2024-03-21 DOI: 10.15212/amm-2024-0010

Yang Liu, Jing Liang, Rui Zhu, Yueying Yang, Yali Wang, Wenyi Wei, Hua Li, Lixia Chen

引用次数: 0

PROTACs Targeting Epigenetic Proteins. 针对表观遗传蛋白质的 PROTACs。

Acta materia medica Pub Date : 2023-10-26 Epub Date: 2023-12-06 DOI: 10.15212/amm-2023-0039

Chao Zhang, Yuna He, Xiuyun Sun, Wenyi Wei, Yanlong Liu, Yu Rao

{"title":"PROTACs Targeting Epigenetic Proteins.","authors":"Chao Zhang, Yuna He, Xiuyun Sun, Wenyi Wei, Yanlong Liu, Yu Rao","doi":"10.15212/amm-2023-0039","DOIUrl":"10.15212/amm-2023-0039","url":null,"abstract":"<p><p>Epigenetics, a field that investigates alterations in gene function that can be inherited without changes in DNA sequence, encompasses molecular pathways such as histone variants, posttranslational modifications of amino acids, and covalent modifications of DNA bases. These pathways modulate the transformation of genotypes into specific phenotypes. Epigenetics plays a substantial role in cell growth, development, and differentiation by dynamically regulating gene transcription and ensuring genomic stability. This regulation is carried out by three key players: writers, readers, and erasers. In recent years, epigenetic proteins have played a crucial role in epigenetic regulation and have gradually become important targets in drug research and development. Targeted therapy is an essential strategy; however, the effectiveness of targeted drugs is often limited by drug resistance, posing a significant dilemma in clinical practice. Targeted protein degradation technologies, including proteolysis-targeting chimeras (PROTACs), have great potential in overcoming drug resistance and targeting undruggable targets. These areas of research are gaining increasing attention to various epigenetic related disease. In this review, we have provided a summary of the recently developed degraders targeting epigenetic readers, writers, and erasers. Additionally, we have outlined new applications for epigenetic protein degraders. Finally, we have addressed several unresolved challenges within the PROTAC field and offered potential solutions from our perspective. As the field continues to advance, the integration of these innovative methodologies holds great promise for addressing the challenges associated with PROTAC development.</p>","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11364368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploitation of platelets for antitumor drug delivery and modulation of the tumor immune microenvironment 血小板用于抗肿瘤药物递送和调节肿瘤免疫微环境

Acta materia medica Pub Date : 2023-05-13 DOI: 10.15212/amm-2023-0005

Jie Guo, Meng Wang, Yong Zhu, F. Watari, Yonghong Xu, Xiao Chen

{"title":"Exploitation of platelets for antitumor drug delivery and modulation of the tumor immune microenvironment","authors":"Jie Guo, Meng Wang, Yong Zhu, F. Watari, Yonghong Xu, Xiao Chen","doi":"10.15212/amm-2023-0005","DOIUrl":"https://doi.org/10.15212/amm-2023-0005","url":null,"abstract":"Platelets are blood components traditionally believed to have fundamental roles in vascular hemostasis and thrombosis. In recent years, platelets have received new attention for their roles in tumorigenesis and progression. On the one hand, platelets are actively recruited by various tumors and comprise a crucial part of the tumor microenvironment (TME), thus inspiring the use of platelets for tumor-targeted drug delivery. To this end, various platelet-based devices have been proposed, such as natural platelets, engineered platelets, platelet membranes, and platelet-derived microparticles. On the other hand, platelets are involved in tumor immunosuppression mechanisms, by directing and/or assisting various tumor-associated immune cells. However, in the context of inflammation and autoimmune diseases, platelets can amplify immune responses by promoting immune cell mobilization and activation, thereby exacerbating tissue damage. Thus, interest is growing in the use of tumor-associated platelets as targets for therapeutic modulation of the TME and augmenting anti-tumor immune responses. In this review, we summarize current advances in exploiting platelets for both antitumor drug delivery and immune modulation of the TME.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41947171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Emerging role of HJURP as a therapeutic target in cancers HJURP作为癌症治疗靶点的新作用

Acta materia medica Pub Date : 2023-05-06 DOI: 10.15212/amm-2023-0008

Jiaqi Tan, Lertnimitphun Peeraphong, Chattarin Ruchawapol, Juan Zhang, Juan Zhao, Wenwei Fu, Li Zhang, Hongxi Xu

引用次数: 2

Inhalable ciprofloxacin/polymyxin B dry powders in respiratory infection therapy 可吸入环丙沙星/多粘菌素B干粉治疗呼吸道感染

Acta materia medica Pub Date : 2023-04-29 DOI: 10.15212/amm-2022-0050

Zhengqi Xu, Hriday Bera, Hengzhuang Wang, Junwei Wang, Dongmei Cun, Yu Feng, Mingshi Yang

{"title":"Inhalable ciprofloxacin/polymyxin B dry powders in respiratory infection therapy","authors":"Zhengqi Xu, Hriday Bera, Hengzhuang Wang, Junwei Wang, Dongmei Cun, Yu Feng, Mingshi Yang","doi":"10.15212/amm-2022-0050","DOIUrl":"https://doi.org/10.15212/amm-2022-0050","url":null,"abstract":"The current study focused on the formulation, physicochemical characterization, and antibacterial susceptibility testing of inhalable spray dried powders containing ciprofloxacin (CIP) and polymyxin B sulfate (PMB). CIP nanosuspensions with an average particle diameter of 435.9 ± 9.3 nm were initially obtained using the wet-milling protocol and subsequently co-spray dried with PMB solutions to yield inhalable dry powders. The Powder X-Ray Diffraction (P-XRD) results showed that the wet-milled CIP nanoparticles were in a 4.8 hydrate state, which were transformed to 3.7 hydrates and amorphous materials after co-spray drying. The PMB remained in an amorphous state in the dry powders. Differential Scanning Calorimetry (DSC) analyses revealed that the glass transition temperatures (Tgs) of the co–spray dried formulations were higher than the Tg of CIP, but lower than the Tg of PMB. Fourier Transform Infrared Spectrometer (FTIR) studies suggested the existence of π - π interactions between CIP and PMB in the co-spray dried powders. These powders also retained antimicrobial effects against Pseudomonas aeruginosa strain PAO1. In addition, the spray-dried powder formulations exhibited satisfactory solid-state stability and aerodynamic characteristics when stored under 3% relative humidity and 20 ± 5 °C for 4 months. Overall, the newly developed inhalable CIP/PMB dry powders are a promising therapeutic strategy for respiratory tract infections.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44299684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular networking as a natural products discovery strategy 分子网络作为一种天然产物发现策略

Acta materia medica Pub Date : 2023-04-25 DOI: 10.15212/amm-2023-0007

Mi Zhang, Kouharu Otsuki, Wei Li

引用次数: 1

Multi-component Chinese medicine formulas for drug discovery: State of the art and future perspectives 用于药物发现的多组份中药配方:现状和未来展望

Acta materia medica Pub Date : 2023-03-30 DOI: 10.15212/amm-2022-0049

Cheng Zhang, Guoming Chen, Guoyi Tang, Xiaoyu Xu, Z. Feng, Yuanjun Lu, Y. Chan, Junyu Wu, Yuanyuan Chen, Lin Xu, Qing-li Ren, Hongchao Yuan, Dong Yang, Zhe-Sheng Chen, Ning Wang, Yibin Feng

{"title":"Multi-component Chinese medicine formulas for drug discovery: State of the art and future perspectives","authors":"Cheng Zhang, Guoming Chen, Guoyi Tang, Xiaoyu Xu, Z. Feng, Yuanjun Lu, Y. Chan, Junyu Wu, Yuanyuan Chen, Lin Xu, Qing-li Ren, Hongchao Yuan, Dong Yang, Zhe-Sheng Chen, Ning Wang, Yibin Feng","doi":"10.15212/amm-2022-0049","DOIUrl":"https://doi.org/10.15212/amm-2022-0049","url":null,"abstract":"For hundreds of years, the drug discovery and development industry has aimed at identifying single components with a clear mechanism of action as desirable candidates for potential drugs. However, this conventional strategy of drug discovery and development has faced challenges including a low success rate and high development costs. Herein, we critically review state-of-the-art drug discovery and development based on multi-component Chinese medicine formulas. We review the policies and application status of new drugs based on multi-component Chinese medicines in the US, China, and the European Union. Moreover, we illustrate several excellent cases of ongoing applications. Biomedical technologies that may facilitate drug discovery and development based on multi-component Chinese medicine formulas are discussed, including network pharmacology, integrative omics, CRISPR gene editing, and chemometrics. Finally, we discuss potential problems and solutions in pre-clinical and clinical research in drug discovery and development based on multi-component Chinese medicine formulas. We hope that this review will promote discussion of the roles of multi-component Chinese medicine formulas in the discovery and development of new drugs for the treatment of human diseases.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43989988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Discovery of a pyridophenoselenazinium-based photosensitizer with high photodynamic efficacy against breast cancer cells 发现一种对乳腺癌症细胞具有高光动力效应的基于吡啶并苯并氮嗪的光敏剂

Acta materia medica Pub Date : 2023-03-23 DOI: 10.15212/amm-2023-0002

Guiling Li, Peixia Li, Qiaoyun Jiang, Qianqian Zhang, Jingru Qiu, Donghai Li, Gang Shan

引用次数: 0

Potential pharmacokinetic interactions in fixed-dose combinations of perindopril/indapamide/amlodipine compared with perindopril/indapamide and amlodipine in healthy Chinese volunteers 培哚普利/吲达帕胺/氨氯地平固定剂量联合用药与培哚普利/吲达帕胺和氨氯地平在中国健康志愿者体内的潜在药代动力学相互作用比较

Acta materia medica Pub Date : 2023-03-18 DOI: 10.15212/amm-2022-0045

Huitao Gao, Hongzhong Liu, Xin Zheng, X. Cui, S. Bricout-Hennel, A. Lucien, Pauline Lauruol, Yaqin Wang, Xue Wang, Hongyun Wang, Chen Rui

{"title":"Potential pharmacokinetic interactions in fixed-dose combinations of perindopril/indapamide/amlodipine compared with perindopril/indapamide and amlodipine in healthy Chinese volunteers","authors":"Huitao Gao, Hongzhong Liu, Xin Zheng, X. Cui, S. Bricout-Hennel, A. Lucien, Pauline Lauruol, Yaqin Wang, Xue Wang, Hongyun Wang, Chen Rui","doi":"10.15212/amm-2022-0045","DOIUrl":"https://doi.org/10.15212/amm-2022-0045","url":null,"abstract":"S05590 is a fixed-dose combination of perindopril tert-butylamine 4 mg/indapamide 1.25 mg, and S06593 is a fixed-dose combination of perindopril arginine 5 mg/indapamide 1.25 mg/amlodipine 5 mg. The purpose of this study was to determine whether pharmacokinetic interactions exist among the components of S06593, compared with S05590 and amlodipine as reference drugs, in healthy Chinese male volunteers after a single oral administration under fasting conditions. A single-center, open-label, randomized, three-period, six-way crossover study was conducted. A total of 42 participants were enrolled and randomized to receive S05590 plus amlodipine, or S06593. The doses of perindopril were 3.34 mg in both S05590 and S06593, calculated as free acid. Blood samples were collected in each treatment period to determine the plasma concentrations of perindopril, indapamide and amlodipine, as well as perindoprilat, the main metabolite of perindopril. A total of 39 participants completed this study. The 90% confidence intervals of the geometric mean ratios of Cmax, AUC0-t and AUC0-∞ for perindopril, perindoprilat, indapamide and amlodipine were all within 80.00–125.00%, thus indicating that S05590 plus amlodipine and S06593 were pharmacokinetically equivalent. During the study, only one serious emergent adverse event was reported, which was deemed not to be associated with the study drug. No serious treatment-associated adverse events were observed.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43836076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0